Incidence of low pressure in the weaning of vasopressor drugs

Phase 4

Recruiting

• Conditions: septicemia not specified; R57.9

• Registration Number: RBR-10smbw65
• Lead Sponsor: Hospital Nossa Senhora da Conceição

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-08-23
• Last Update Posted: 29 May 2023
• Study Completion: 2023-12-31

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Adult patients; both genders; older than 18 years; hospitalized for septic shock; in use of noradrenaline and vasopressin associated

Exclusion Criteria

Patients in whom the reduction of these vasopressors (noradrenaline and vasopressin) is related to the introduction of adrenaline or is related to the process of withdrawal of therapeutic support (therapeutic limitation)

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The incidence of hypotension will be evaluated in the first 24 hours after the beginning of the reduction of one of the vasoactive drugs (noradrenaline or vasopressin), through medical records and prescriptions. Hypotension is defined as a fall in mean arterial pressure below 65 mmHg, triggering one or more of the following measures: a) administration of an aliquot of crystalloid or colloid, b) increase in the dose of the remaining vasoactive drug, or c) reinstitution of the vasoactive drug paused.

Secondary Outcome Measures

Name	Time	Method
Patients' mortality will be evaluated in a 28-day follow-up.;The time (in days) of hospitalization in the Intensive Care Unit will be evaluated.;To quantify the time in use of vasoactive drugs, after the reduction of the first drug (noradrenaline or vasopressin), in days, in a follow-up of up to seven days. The use of vasoactive drugs is understood to mean the use of any vasopressor drug. Interruption means suspension for at least 24 hours.;To quantify the incidence of arrhythmias with hemodynamic repercussions, in the first 24 hours after the reduction of the first drug (noradrenaline or vasopressin). Events in which hemodynamic worsening required electrical or chemical cardioversion are included in this group.;To quantify the incidence of patients on hemodialysis, whether intermittent or continuous, in the first 72 hours after the reduction of the first drug (noradrenaline or vasopressin). Chronic dialysis patients are excluded from this analysis.